While the tragedy’s scope is numerically enormous causing more than 8 million fatality annually, Tobacco use remains a leading cause of preventable death worldwide. In response, the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) has galvanized global efforts to implement evidence-based tobacco control policies. This review synthesizes recent evidence on the impact of key FCTC-recommended policies, taxation and price increases, smoke-free laws, warning labels, advertising bans, and cessation support, on smoking prevalence from a global perspective. The 1. 4 trillion annual economic burden is not merely a byproduct of addition but as a result of deliberate industry efforts to exploit regulatory weaknesses in emerging economies. A narrative review of scientific literature published between 2015 and 2024 was conducted, synthesizing evidence from 58 primary sources, drawing on longitudinal studies, cross-country comparisons, and reports from international organizations like the WHO and the World Bank. A narrative approach was selected over a systematic review to allow for a broader qualitative synthesis of the complex interplay for a broader qualitative synthesis of the complex interplay between legal frameworks, regional sociopolitical factors and evolving industry tactics which strictly quantitatively meta-analysis. The evidence consistently demonstrates that comprehensive tobacco control policies are effective in reducing smoking prevalence. MPOWER policy packages, when implemented at a high level of achievement, are associated with significant declines in smoking rates. However, the pace and comprehensiveness of policy adoption vary significantly by region and country income level, leading to disparities in their effectiveness. Low- and middle-income countries (LMICs), which face intense tobacco industry interference, often lag in implementation despite bearing a growing burden of tobacco-related disease. The global fight against tobacco is yielding positive results, but progress is uneven. Accelerating the implementation of the WHO FCTC’s MPOWER measures, particularly in LMICs, is critical to further reducing global smoking prevalence and achieving associated public health gains. Future challenges include addressing novel tobacco products and combating persistent tobacco industry tactics, and overcoming significant funding deficits and the lack of robust national tobacco control systems.
Okposio et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: